Shares of China Medical (CMED -19.5%) plunge after Glaucus Research alleges the medical device maker's CEO "orchestrated an acquisition to embezzle roughly $20-$23 million from the public company." Glaucus says CMED overpaid for the acquisition from an entity it believes is secretly related to the company's CEO. CMED denies the allegations.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs